Vaxcyte, Inc. (PCVX)
| Market Cap | 8.44B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -766.63M |
| Shares Out | 143.92M |
| EPS (ttm) | -5.63 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 857,533 |
| Open | 60.12 |
| Previous Close | 59.72 |
| Day's Range | 58.27 - 60.52 |
| 52-Week Range | 28.09 - 65.00 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 88.25 (+50.42%) |
| Earnings Date | May 7, 2026 |
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused b... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for PCVX stock is "Strong Buy." The 12-month stock price target is $88.25, which is an increase of 50.42% from the latest price.
News
Vaxcyte Transcript: 25th Annual Needham Virtual Healthcare Conference
Upcoming 12–15 months will see pivotal data from adult and infant VAX-31 studies, with a BLA filing targeted by end of next year and potential approval in 2028. Market growth is driven by expanded adult vaccination and global recommendations, while strong financials support continued development.
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside...
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
OPUS-1 Phase 3 Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines (PCVs) Through Head-to-Head Safety, Tolerability and Immunogenicity Comparisons of VAX-31 with Capva...
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Based on the Strength of Unprecedented Results from the Positive Phase 1/2 Study in Adults Aged 50 and Older, Vaxcyte Advanced VAX-31 High Dose into Comprehensive Phase 3 Adult Program; Topline Data f...
Vaxcyte Transcript: Leerink Global Healthcare Conference 2026
The company is advancing its 31-valent pneumococcal vaccine, with pivotal phase III results expected in Q4 and additional studies supporting a BLA filing by end of next year. Higher-dose strategies in infants and a novel Group A Strep vaccine entering the clinic highlight a robust pipeline and regulatory confidence.
Vaxcyte Transcript: TD Cowen 46th Annual Health Care Conference
VAX-31, a 31-valent pneumococcal vaccine, is advancing through pivotal phase 3 trials with key data expected this year and next. Innovative conjugation technology enables broader serotype coverage and improved immune responses, while regulatory and market dynamics favor expanded adult vaccination. Group A Strep vaccine development and global market growth further strengthen the outlook.
Vaxcyte Earnings Call Transcript: Q4 2025
Strong clinical and operational progress in 2025, with late-stage VAX-31 trials advancing and a robust financial position supporting expansion. Manufacturing readiness and resumed pipeline development position the company for a catalyst-rich 2026–2027.
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies Underway to Support Planned BLA Submission Topline Safety, To...
Vaxcyte Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Pneumococcal vaccine innovation is driving expansion into global adult and pediatric markets, with VAX-31 showing best-in-class data and aiming for broad serotype coverage. Strong financials support a pivotal phase 3 program and potential 2028 launch.
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
SAN CARLOS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today that it will report financial results for the fourth qu...
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside ...
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten pu...
Vaxcyte Announces Pricing of $550 Million Public Offering
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the pricing of an underwritten public offering of commo...
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN CARLOS, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced an underwritten public offering o...
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
VAX-31 Adult Indication: Vaxcyte Doses First Participants in Phase 3 Study Evaluating Concomitant Administration of VAX-31 and Seasonal Influenza Vaccine (OPUS-2) and Expects to Initiate Phase 3 Study...
This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%.
Vaxcyte keeps its place among Mizuho Securities top picks entering 2026.
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Trial Design Finalized in Consultation and Alignment with U.S. Food and Drug Administration Study Designed to Establish a New Standard for Adult Pneumococcal Conjugate Vaccines Through Head-to-Head S...
Vaxcyte Transcript: Evercore ISI 8th Annual HealthCONx Conference
Regulatory and clinical plans remain on track, with phase III adult and infant studies advancing and no major changes required by recent FDA guidance. Dose optimization in infants aims to improve immunogenicity, and financial resources are sufficient to support all key programs through mid-2028.
Vaxcyte Transcript: Jefferies London Healthcare Conference 2025
A 31-Valent Pneumococcal Conjugate Vaccine is advancing to phase III in adults, with strong phase II data showing superior coverage and immune response. The market is expected to grow rapidly, especially in adults, and manufacturing capacity is being expanded to meet global demand.
Vaxcyte Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong clinical progress was reported for both adult and infant pneumococcal vaccine programs, with pivotal phase 3 studies set to begin and robust immune responses observed. Market expansion is driven by broader vaccine coverage and new age-based recommendations, while commercial and manufacturing readiness advances.
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
Final Data from VAX-24 Infant Phase 2 Dose-Finding Study Consistent with Previously Reported Positive Interim Data; Provide Additional Evidence Supporting Higher VAX-31 Doses Being Evaluated in Ongoin...
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
New Agreement with Thermo Fisher Scientific Expands Domestic Capacity to Support Future Commercial Manufacturing of Vaxcyte's Broad-Spectrum Pneumococcal Conjugate Vaccine Candidates
Vaxcyte Transcript: Cantor Global Healthcare Conference 2025
A proprietary vaccine platform is advancing a 31-valent pneumococcal vaccine, with phase III adult studies starting in Q4 and infant studies progressing with optimized dosing. Market growth is expected in the adult segment, and a strong cash position supports operations through mid-2028.
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococ...